CLQ Overview Deck

Editor's Notes

• #4: But to do that, we face two key challenges: We need to learn from many more patients than we do today – in fact, we need to learn from all of them; and We have to harness data in powerful new ways
• #5: As you can see here, the left represents an individual’s genomic make-up. And the right are clinical data that reflect a patient’s unique environment, behaviors and preferences. To make a meaningful impact on cancer care, we can’t take either of these in isolation.
• #6: Take lung cancer for example… soon, every cancer will be a rare cancer, defined by unique molecular characteristics Brings vast increase in number of possibilities and the information physicians have to make sense of Only way to do this is through powerful new data analytic tools
• #7: Precision medicine also adds a new level of complexity to cancer care, creating the need for information management
• #8: Right now, we essentially only learn from 3 percent of patients – those who participate in clinical trials
• #9: These clinical trial patients rarely reflect the real-world patients we see in clinics The only way to keep pace with expanding scientific possibilities is to expand the number and diversity of the patients we can learn from
• #10: This is the cancer data architecture – in the inner circle, you have various sources of health data including data from EHRs, and clinical and genomic data that are critically important to patient care. But these data are all housed in different places – in their own information systems and data repositories. We have to figure out how we can capture, move and share this information. We need to understand how these data are structured, map that to a common model, move the data around from one warehouse to another, create information exchanges, and establish standards to transmit data. If we do that we achieve interoperability and have data liquidity. And this is where SAP comes in – because SAP’s HANA technology can move massive amounts of data, precisely, and in real time.
• #11: [Dr. Yu – this is an adaptation of your slide on data to learning, to show how raw data can be transformed to what CancerLinQ aims to get at, increasing the understanding and real-world applicability of information. Please let us know if we captured it correctly or if you would like to revise]
• #12: [Dr. Yu – we took the next few slides from the slides you shared with us; let us know if your talking points for these slides fit with what comes before and after this section]
• #14: Each stage of CancerLinQ will deliver successively more powerful tools and insights to physicians, researchers, patients and others in the cancer community. The first version, being rolled out later this year, features several core components of the CancerLinQ system.
• #15: First, doctors will have powerful new ways to visualize data from their electronic health records. For example – They’ll be able to view a visual, longitudinal record of any given patient’s care over time – as you see here.   In effect, CancerLinQ gives them – in an instant – the story of that patient’s characteristics, the care they’ve received, and the outcomes they’ve experienced. Until now, most physicians have had no simple way of constructing something like this.
• #16: Doctors can dig down into any part of that story to: Better understand why their patient might be experiencing some new health problem See if any opportunities have been missed 
• #17: Second, the physician will have a new way to see the quality of care they’re delivering – at any moment.   And not just that – they’ll see if there are specific patients who are currently in need of an intervention to meet standards of care. Example of a physician who is meeting a given quality measure 80 percent of the time. CancerLinQ will identify what we call an “actionable patient” – flagging a patient that requires follow-up care. So if she’s not already scheduled for that care, the practice can reach out and ask her to come in to discuss. The big shift here is from measuring quality retrospectively – after the fact – to intervening in real time to ensure that quality is achieved.
• #21: Primary goal is QUALITY. This will deliver benefits for multiple audiences. Educate and empower patients by linking them to their cancer care teams and providing personalized treatment information at their fingertips. Improve personalized treatment decisions by cancer care teams by capturing patient information in real time at the point of care; providing real-time decision support tailored to each patient and his or her cancer; and automatically reporting on the quality of care compared with clinical guidelines and the outcomes of other patients. Create a powerful new de-identified data source for use in real-world quality and comparative effectiveness studies, and to generate new ideas for clinical research.